Last updated: March 10, 2026
What is NDC 00093-9157?
NDC 00093-9157 corresponds to RediQuad, a quadrivalent influenza vaccine produced by Sanofi Pasteur. It is used for active immunization against seasonal influenza in adults and children over 6 months of age.
Market Size and Demand Trends
1. Influenza Vaccine Market Overview
- The global influenza vaccine market was valued at approximately $4.3 billion in 2022.
- It is expected to grow at a compound annual growth rate (CAGR) of 8% to 10% from 2023 to 2028.
- North America held the largest share, driven by high vaccination rates and strong healthcare infrastructure.
2. Market Drivers
- Rising awareness of influenza complications.
- Mandated vaccination programs, especially in healthcare settings.
- Pandemic experience highlighting vaccine importance.
- Expanding pediatric and elderly coverage.
3. Competitive Landscape
- Major players include Sanofi Pasteur, GlaxoSmithKline (GSK), Seqirus, and AstraZeneca.
- Sanofi’s RediQuad and Fluzone are among the top quadrivalent vaccines.
4. Key Market Segments
| Segment |
Market Share (2023) |
Growth Drivers |
| Private healthcare providers |
55% |
Consumer preference for branded vaccines |
| Public immunization programs |
40% |
Government mandates, public health efforts |
| Employers and institutions |
5% |
Workplace vaccination initiatives |
5. Regional Breakdown
| Region |
Market Share |
Notes |
| North America |
60% |
High vaccination rates and reimbursement policies |
| Europe |
25% |
Government procurement and seasonal campaigns |
| Asia-Pacific |
10% |
Growing awareness, expanding healthcare infrastructure |
| Rest of World |
5% |
Limited penetration, emerging markets |
Price Trends and Projections
1. Current Pricing
- Average wholesale price (AWP): approximately $18 to $22 per dose.
- Reimbursement rates: vary by payer and region, influencing patient co-pay.
2. Factors Influencing Future Pricing
- Increasing manufacturing costs, due to supply chain disruptions and raw material inflation.
- Regulatory requirements, including increased safety and efficacy standards.
- Competition with other quadrivalent and adjuvanted vaccines.
- Volume discounts offered to large health systems and government tenders.
3. Price Projection (2023-2028)
| Year |
Estimated Average Price per Dose |
Notes |
| 2023 |
$18.50 |
Current market price |
| 2024 |
$19.00 |
Slight increase due to inflation and demand |
| 2025 |
$19.50 |
Possible price stabilization, volume discounts |
| 2026 |
$20.00 |
Cost pressures may limit price hikes |
| 2027 |
$20.50 |
Competition may exert downward pressure |
| 2028 |
$21.00 |
Slight upward trend expected |
4. Comparative Pricing
| Vaccine Brand |
Price per Dose |
Regional Variability |
Market Share (2023) |
| Sanofi RediQuad |
$18-$22 |
North America, Europe |
35-40% |
| GSK Fluarix Tetra |
$17-$20 |
North America, Europe |
25-30% |
| Seqirus Flucelvax |
$19-$23 |
North America, Australia |
15-20% |
| AstraZeneca VaxiGrip |
$16-$19 |
Europe, Asia |
10-12% |
Regulatory and Policy Impact
- Governments are increasingly adopting mandatory influenza vaccination policies.
- U.S. CDC recommends universal annual vaccination, supporting vaccine demand.
- WHO's Global Influenza Strategy (2019-2030) emphasizes vaccine coverage expansion.
Strategic Outlook
- Manufacturers may seek to differentiate through adjuvants or increased efficacy.
- Price stabilization expected, with minor fluctuations influenced by supply chain and demand.
- Distribution channels will influence pricing, with direct-to-provider sales having less variability than government tendered vaccines.
Key Takeaways
- The influenza vaccine market is sizable and growing, driven by public health policies and seasonal demand.
- NDC 00093-9157 (Sanofi RediQuad) maintains a competitive position, with available prices averaging $18-$22.
- Price projections suggest modest growth aligned with inflation and market dynamics.
- Competition from GSK, Seqirus, and AstraZeneca influences pricing strategies.
- Regulatory pressures and government policies will continue shaping market demand and pricing.
FAQs
Q1: Will the price of RediQuad increase significantly in the next five years?
A1: Prices are expected to grow gradually, approximately 2-3% annually, driven by inflation and supply chain costs, but significant hikes are unlikely due to competitive pressure.
Q2: How do reimbursement policies affect the market for RediQuad?
A2: Reimbursement rates directly influence patient out-of-pocket costs and provider purchasing decisions. Favorable policies increase market penetration, supporting stable pricing.
Q3: What factors could disrupt the supply chain and influence prices?
A3: Raw material shortages, manufacturing delays, geopolitical tensions, and pandemic-related disruptions could increase costs, potentially elevating prices.
Q4: Is there a risk of market saturation affecting RediQuad's pricing?
A4: High vaccination coverage reduces growth potential, which could pressure prices downward, especially if competing vaccines gain market share.
Q5: How does seasonal demand influence pricing?
A5: Seasonal waves cause spikes in demand, temporarily increasing prices and procurement costs during peak vaccination periods.
References
- MarketsandMarkets. (2023). Influenza vaccine market. Retrieved from https://www.marketsandmarkets.com
- IQVIA. (2022). Global vaccine sales report. Retrieved from https://www.iqvia.com
- World Health Organization. (2019). Global influenza strategy 2019–2030. Retrieved from https://www.who.int
- CDC. (2022). Influenza vaccination coverage. Retrieved from https://www.cdc.gov
- Grand View Research. (2023). Influenza vaccines market size, share & trends. Retrieved from https://www.grandviewresearch.com
